Zurich Coronavirus Vaccination Cohort: an observational study to assess longer-term immune responses and health status after coronavirus (COVID-19) vaccination in Zurich, Switzerland

Zurich SARS-CoV-2 Vaccine Cohort (ZVAC): Development of immunity after SARS-CoV-2 vaccination

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN15499304

Enrollment

800

Registered

2021-03-19

Start date

2021-03-22

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-Cov-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection)

Interventions

Current intervention as of 30/05/2022: Individuals receiving any of the SARS-CoV-2 vaccines approved in Switzerland at the Corona Center of the UZH, who are randomly selected and invited for study par

usually day of first vaccine dose), and 3-4 weeks, 6 weeks, 3 months, 6 months, 9 months and 12 months after baseline. Those consenting to further participation in the study will receive up to four ad

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Individuals receiving any of the SARS-CoV-2 vaccines approved in Switzerland at the Corona Center of the UZH 2. Aged =18 years, 3. Able to follow the study procedures 4. Providing informed consent

Exclusion criteria

Exclusion criteria: 1. Having insufficient knowledge of the German language 2. Individuals whose primary residence is outside of the Canton of Zurich 3. Previously received SARS-CoV-2 vaccine

Design outcomes

Primary

Measure	Time frame
Current primary outcome measures as of 08/06/2022: Measured using blood samples: 1. Presence of anti-SARS-CoV-2 IgG antibodies before receiving the first dose of a vaccine (baseline) and at 3-4 weeks, 6 weeks, 3 months, 6 months, 12 months, and every 6 months up to 3 years after baseline 2. Presence of SARS-CoV-2 antigen-specific T cells before receiving the first dose of a vaccine (baseline) and at 3-4 weeks, 6 weeks, 3 months, 6 months, 12 months, and every 6 months up to 3 years after baseline _____ Previous primary outcome measures: Measured using blood samples: 1. Presence of anti-SARS-CoV-2 IgG antibodies before receiving the first dose of a vaccine (baseline), at 3-4 weeks, at 6 weeks, and at 3, 6 and 12 months after baseline 2. Presence of SARS-CoV-2 antigen-specific T cells before receiving the first dose of a vaccine (baseline), and at 3-4 weeks, at 6 weeks, and at 3, 6 and 12 months after baseline	—

Measure

Time frame

Current primary outcome measures as of 08/06/2022: Measured using blood samples: 1. Presence of anti-SARS-CoV-2 IgG antibodies before receiving the first dose of a vaccine (baseline) and at 3-4 weeks, 6 weeks, 3 months, 6 months, 12 months, and every 6 months up to 3 years after baseline 2. Presence of SARS-CoV-2 antigen-specific T cells before receiving the first dose of a vaccine (baseline) and at 3-4 weeks, 6 weeks, 3 months, 6 months, 12 months, and every 6 months up to 3 years after baseline _____ Previous primary outcome measures: Measured using blood samples: 1. Presence of anti-SARS-CoV-2 IgG antibodies before receiving the first dose of a vaccine (baseline), at 3-4 weeks, at 6 weeks, and at 3, 6 and 12 months after baseline 2. Presence of SARS-CoV-2 antigen-specific T cells before receiving the first dose of a vaccine (baseline), and at 3-4 weeks, at 6 weeks, and at 3, 6 and 12 months after baseline

—

Secondary

Measure	Time frame
Current secondary outcome measures as of 17/06/2022: 1. Proportion of individuals with neutralizing antibodies measured using blood test before receiving the first dose of a vaccine (baseline) and at 3-4 weeks, 6 weeks, 3 months, 6 months, 12 months, and every 6 months up to 3 years after baseline 2. Humoral (IgG antibodies) and cellular response (T cells) measured using blood test before receiving the first dose of a vaccine (baseline) and at 3-4 weeks, 6 weeks, 3 months, 6 months, 12 months, and every 6 months up to 3 years after baseline 3. Proportion of individuals who received a SARS-CoV-2 vaccine who experience a SARS-CoV-2 infection and determination of the severity of that infection measured using a questionnaire at baseline, and 3-4 weeks, 6 weeks, 3 months, 6 months, 9 months and 12 months, and every 6 months up to 3 years after baseline 4. Proportion of individuals who received a SARS-CoV-2 vaccine who experience adverse effects and determination of the severity and consequence of that adverse effect measured using a diary during the first 3 months after vaccination 5. Proportion of individuals who received a SARS-CoV-2 vaccine who are later exposed to SARS-CoV-2 and determination of the exposure context measured using a questionnaire at baseline, and 3-4 weeks, 6 weeks, 3 months, 6 months, 9 months and 12 months, and every 6 months up to 3 years after baseline _____ Previous secondary outcome measures as of 08/06/2022: 1. Proportion of individuals with neutralizing antibodies measured using blood test before receiving the first dose of a vaccine (baseline) and at 3-4 weeks, 6 weeks, 3 months, 6 months, 12 months, and every 6 months up to 3 years after baseline 2. Humoral (IgG antibodies) and cellular response (T cells) measured using blood test before receiving the first dose of a vaccine (baseline) and at 3-4 weeks, 6 weeks, 3 months, 6 months, 12 months, and every 6 months up to 3 years after baseline 3. Proportion of individuals who received a	—

Measure

Time frame

Current secondary outcome measures as of 17/06/2022: 1. Proportion of individuals with neutralizing antibodies measured using blood test before receiving the first dose of a vaccine (baseline) and at 3-4 weeks, 6 weeks, 3 months, 6 months, 12 months, and every 6 months up to 3 years after baseline 2. Humoral (IgG antibodies) and cellular response (T cells) measured using blood test before receiving the first dose of a vaccine (baseline) and at 3-4 weeks, 6 weeks, 3 months, 6 months, 12 months, and every 6 months up to 3 years after baseline 3. Proportion of individuals who received a SARS-CoV-2 vaccine who experience a SARS-CoV-2 infection and determination of the severity of that infection measured using a questionnaire at baseline, and 3-4 weeks, 6 weeks, 3 months, 6 months, 9 months and 12 months, and every 6 months up to 3 years after baseline 4. Proportion of individuals who received a SARS-CoV-2 vaccine who experience adverse effects and determination of the severity and consequence of that adverse effect measured using a diary during the first 3 months after vaccination 5. Proportion of individuals who received a SARS-CoV-2 vaccine who are later exposed to SARS-CoV-2 and determination of the exposure context measured using a questionnaire at baseline, and 3-4 weeks, 6 weeks, 3 months, 6 months, 9 months and 12 months, and every 6 months up to 3 years after baseline _____ Previous secondary outcome measures as of 08/06/2022: 1. Proportion of individuals with neutralizing antibodies measured using blood test before receiving the first dose of a vaccine (baseline) and at 3-4 weeks, 6 weeks, 3 months, 6 months, 12 months, and every 6 months up to 3 years after baseline 2. Humoral (IgG antibodies) and cellular response (T cells) measured using blood test before receiving the first dose of a vaccine (baseline) and at 3-4 weeks, 6 weeks, 3 months, 6 months, 12 months, and every 6 months up to 3 years after baseline 3. Proportion of individuals who received a

—

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026